Related Experiment Videos
Domperidone in defective and insufficient lactation
Summary
Domperidone effectively stimulates prolactin (PRL) levels, aiding lactogenesis and galactopoiesis in women with lactation difficulties. This anti-dopaminergic drug shows significant promise for supporting successful breastfeeding without adverse effects.
Area of Science:
- Endocrinology
- Pharmacology
- Reproductive Medicine
Background:
- Hypothalamic dopamine inhibits prolactin (PRL) secretion.
- Anti-dopaminergic drugs are explored for stimulating lactation.
- Domperidone (DOM) is a peripherally acting anti-dopaminergic agent.
Purpose of the Study:
- To evaluate domperidone's efficacy in inducing lactogenesis in women with a history of defective lactation.
- To assess domperidone's effectiveness in maintaining lactation (galactopoiesis) in women with insufficient milk supply.
- To compare domperidone treatment with placebo in these two groups.
Main Methods:
- Domperidone or placebo administered to puerperal women with lactation issues.
- Group A: defective lactogenesis (n=8 DOM, n=7 placebo).
- Group B: insufficient lactation (n=9 DOM, n=8 placebo).
- Plasma PRL levels measured before and after suckling.
- Milk yield assessed during treatment.
Main Results:
- Domperidone significantly increased baseline PRL levels compared to placebo (P<0.01).
- Domperidone treatment resulted in significantly higher daily milk yield versus placebo (P<0.01).
- No significant side-effects were reported with domperidone use.
Conclusions:
- Domperidone is effective in inducing and maintaining lactation.
- The drug demonstrates high usefulness for supporting successful breastfeeding.
- Positive outcomes suggest domperidone's value for infant health and development.